About Humana (NYSE:HUM)
Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group and Specialty segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Managed Health Care
- Sub-Industry: Managed Health Care
- Symbol: NYSE:HUM
- CUSIP: 44485910
- Web: www.humana.com
- Market Cap: $35.52 billion
- Outstanding Shares: 144,517,000
- 50 Day Moving Avg: $245.62
- 200 Day Moving Avg: $236.63
- 52 Week Range: $165.03 - $259.76
Sales & Book Value:
- Trailing P/E Ratio: 20.22
- Foreward P/E Ratio: 19.98
- P/E Growth: 1.58
- Annual Revenue: $53.87 billion
- Price / Sales: 0.66
- Book Value: $75.79 per share
- Price / Book: 3.24
- Annual Dividend: $1.60
- Dividend Yield: 0.7%
- EBITDA: $2.66 billion
- Net Margins: 3.37%
- Return on Equity: 15.85%
- Return on Assets: 5.76%
- Debt-to-Equity Ratio: 0.39%
- Current Ratio: 1.65%
- Quick Ratio: 1.65%
- Average Volume: 1.08 million shs.
- Beta: 0.86
- Short Ratio: 3.51
Frequently Asked Questions for Humana (NYSE:HUM)
What is Humana's stock symbol?
Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."
How often does Humana pay dividends? What is the dividend yield for Humana?
Humana declared a dividend on Thursday, August 17th. Stockholders of record on Friday, September 29th will be given a dividend of $0.40 per share on Monday, October 16th. The ex-dividend date of this dividend is Thursday, September 28th. View Humana's Dividend History.
How will Humana's stock buyback program work?
Humana announced that its board has approved a share buyback plan on Tuesday, April 11th 2017, which authorizes the company to buyback $2,250,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 7.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its stock is undervalued.
How were Humana's earnings last quarter?
Humana Inc. (NYSE:HUM) released its quarterly earnings results on Wednesday, August, 2nd. The company reported $3.49 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the business earned $2.30 EPS. View Humana's Earnings History.
When will Humana make its next earnings announcement?
What guidance has Humana issued on next quarter's earnings?
Humana issued an update on its FY17 earnings guidance on Friday, September, 1st. The company provided earnings per share guidance of ~$11.50 for the period, compared to the Thomson Reuters consensus estimate of $11.51.
Where is Humana's stock going? Where will Humana's stock price be in 2017?
20 analysts have issued 1-year target prices for Humana's stock. Their predictions range from $200.00 to $300.00. On average, they anticipate Humana's share price to reach $253.11 in the next twelve months. View Analyst Ratings for Humana.
What are analysts saying about Humana stock?
Here are some recent quotes from research analysts about Humana stock:
- 1. According to Zacks Investment Research, "Humana is well poised to grow on its strong government business. Its top-line has been witnessing an uptrend from past many years. Sufficient generation of cash flow has helped the company take up several capital deployment initiatives aimed at enhancing shareholders’ value. Humana’s sound balance sheet and disciplined capital management remains a positive. Following its strong second-quarter 2017 results, it raised its 2017 adjusted EPS guidance. The company has also seen the Zacks Consensus Estimate for the current year earnings being revised upward in last 30 days. Although the shares have performed in line with the industry in a year's time, its strong fundamentals are likely to help the stock in gaining momentum going forward. However, the company's individual commercial business has remained a drag over past few years. The company will release third quarter results on Nov 8, 2017." (10/17/2017)
- 2. Cantor Fitzgerald analysts commented, "We are transferring coverage of Humana (HUM) and rate the shares at Neutral; our 12-month DCF-based price target is $186. The shares trade 6% above our price target, probably due in part to continued speculation that HUM remains a takeover candidate. We believe there is a low probability that AET will successfully appeal a recent court decision which ruled against the merger (if it even decides to appeal the decision). We assign a low probability that HUM will be acquired, at least in the short term. HUM's losses relating to the Affordable Care Act will shrink in 2017 and 2018. Medicare continues to perform well, recognizing that HUM 2018 MA reimbursement could be impacted by a reduction in its star ratings. With about 6% downside to our target price, our rating is Neutral." (2/6/2017)
Who are some of Humana's key competitors?
Who are Humana's key executives?
Humana's management team includes the folowing people:
- Kurt J. Hilzinger, Independent Chairman of the Board
- Bruce D. Broussard, President, Chief Executive Officer, Director
- Brian A. Kane, Chief Financial Officer, Senior Vice President
- Timothy S. Huval, Chief Human Resource Officer, Senior Vice President
- Brian P. LeClaire, Senior Vice President, Chief Information Officer
- Sam Deshpande, Senior Vice President, Chief Risk Officer
- Christopher M. Todoroff, Senior Vice President, General Counsel
- Roy A. Beveridge M.D., Senior Vice President, Chief Medical Officer
- Jody L. Bilney, Senior Vice President, Chief Consumer Officer
- Christopher H. Hunter, Senior Vice President, Chief Strategy Officer
Who owns Humana stock?
Humana's stock is owned by many different of retail and institutional investors. Top institutional investors include APG Asset Management N.V. (0.31%), PGGM Investments (0.12%), Robeco Institutional Asset Management B.V. (0.09%), Hermes Investment Management Ltd. (0.06%), Shell Asset Management Co. (0.05%) and State Treasurer State of Michigan (0.03%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.
Who sold Humana stock? Who is selling Humana stock?
Humana's stock was sold by a variety of institutional investors in the last quarter, including Quotient Investors LLC, State Treasurer State of Michigan, Quantitative Systematic Strategies LLC, Baker Ellis Asset Management LLC and Rockefeller Financial Services Inc.. Company insiders that have sold Humana stock in the last year include Brian P Leclaire, Bruce D Broussard, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy S Huval and William Kevin Fleming. View Insider Buying and Selling for Humana.
Who bought Humana stock? Who is buying Humana stock?
Humana's stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., PGGM Investments, Shell Asset Management Co., Hermes Investment Management Ltd., Robeco Institutional Asset Management B.V., Oakbrook Investments LLC, Mutual of America Capital Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for Humana.
How do I buy Humana stock?
Shares of Humana can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Humana's stock price today?
MarketBeat Community Rating for Humana (NYSE HUM)MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Humana stock can currently be purchased for approximately $245.81.
Consensus Ratings for Humana (NYSE:HUM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||8 Hold Ratings, 12 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.60)|
|Consensus Price Target: ||$253.11 (2.97% upside)|Consensus Price Target History for Humana (NYSE:HUM)
Analysts' Ratings History for Humana (NYSE:HUM)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/16/2017||BMO Capital Markets||Initiated Coverage||Outperform||$300.00||N/A|
|10/13/2017||Jefferies Group LLC||Reiterated Rating||Hold||$257.00||N/A|
|10/10/2017||Royal Bank Of Canada||Reiterated Rating||Hold||$245.00||N/A|
|10/9/2017||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||$253.00||N/A|
|9/20/2017||Cowen and Company||Reiterated Rating||Outperform||$230.00 -> $275.00||Medium|
|8/17/2017||Morgan Stanley||Boost Price Target||Overweight||$269.00 -> $276.00||Low|
|8/7/2017||Deutsche Bank AG||Boost Price Target||Hold||$234.00 -> $243.00||Low|
|8/3/2017||Cantor Fitzgerald||Reiterated Rating||Neutral||$200.00 -> $223.00||Low|
|8/3/2017||Oppenheimer Holdings, Inc.||Boost Price Target||Outperform||$236.00 -> $255.00||Medium|
|8/3/2017||Credit Suisse Group||Reiterated Rating||Outperform||$250.00 -> $260.00||High|
|8/3/2017||Piper Jaffray Companies||Boost Price Target||Overweight||$280.00||High|
|7/14/2017||Bank of America Corporation||Boost Price Target||Buy||$270.00 -> $275.00||Low|
|6/28/2017||Citigroup Inc.||Initiated Coverage||Buy -> Buy||$275.00||Medium|
|6/9/2017||Argus||Upgrade||Hold -> Buy||$260.00||Low|
|5/30/2017||Leerink Swann||Boost Price Target||Outperform||$250.00 -> $265.00||Low|
|4/25/2017||Evercore ISI||Reiterated Rating||Outperform||$240.00||Low|
|1/24/2017||Stifel Nicolaus||Downgrade||Buy -> Hold||$214.00 -> $210.00||N/A|
|1/9/2017||Barclays PLC||Reiterated Rating||Hold||$217.00||N/A|
|12/4/2016||Susquehanna Bancshares Inc||Reiterated Rating||Neutral||$180.00 -> $200.00||N/A|
|7/22/2016||FBR & Co||Lower Price Target||Mkt Perform||$220.00 -> $170.00||N/A|
Earnings History for Humana (NYSE:HUM)Earnings History by Quarter for Humana (NYSE HUM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$3.08||$3.49||$13.61 billion||$13.53 billion||View||Listen|
|5/3/2017||Q1 2017||$2.55||$2.75||$13.61 billion||$13.76 billion||View||N/A|
|2/8/2017||Q416||$2.05||$2.09||$13.55 billion||$12.88 billion||View||N/A|
|11/4/2016||Q316||$3.09||$3.18||$13.41 billion||$13.69 billion||View||N/A|
|8/3/2016||Q216||$2.23||$2.30||$13.59 billion||$14.00 billion||View||N/A|
|5/4/2016||Q1||$1.81||$1.86||$13.80 billion||$13.80 billion||View||N/A|
|2/10/2016||Q415||$1.45||$1.45||$13.51 billion||$13.40 million||View||N/A|
|11/6/2015||Q315||$2.13||$2.16||$13.64 billion||$13.36 billion||View||N/A|
|7/29/2015||Q215||$1.63||$1.67||$13.81 billion||$13.73 billion||View||N/A|
|4/29/2015||Q115||$2.54||$2.47||$13.51 billion||$13.80 billion||View||Listen|
|2/4/2015||Q414||$1.16||$1.09||$12.41 billion||$12.23 million||View||Listen|
|11/7/2014||Q314||$2.01||$1.85||$12.34 billion||$12.24 billion||View||Listen|
|7/30/2014||Q214||$2.19||$2.19||$11.93 billion||$12.22 billion||View||Listen|
|5/7/2014||Q114||$1.94||$2.35||$11.45 billion||$11.71 billion||View||Listen|
|2/5/2014||Q413||$0.95||($0.19)||$10.23 billion||$10.20 billion||View||Listen|
|11/6/2013||Q313||$2.14||$2.31||$10.27 billion||$10.00 billion||View||Listen|
|7/31/2013||Q2 2013||$2.46||$2.63||$10.36 billion||$10.32 billion||View||Listen|
|5/1/2013||Q1 2013||$1.80||$2.95||$10.23 billion||$10.49 billion||View||Listen|
|2/4/2013||Q4 2012||$1.07||$1.19||$9.73 billion||$9.56 billion||View||Listen|
|11/5/2012||Q312||$2.05||$2.62||$9.86 billion||$9.65 billion||View||N/A|
Earnings Estimates for Humana (NYSE:HUM)
2017 EPS Consensus Estimate: $10.86
2018 EPS Consensus Estimate: $12.20
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Humana (NYSE:HUM)
|Most Recent Dividend:||10/16/2017|
|Dividend Growth:||3.10% (3 Year Average)|
|Payout Ratio:||13.06% (Trailing 12 Months of Earnings) |
13.83% (Based on This Year's Estimates)
13.01% (Based on Next Year's Estimates)
|Track Record:||6 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Humana (NYSE HUM)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Humana (NYSE:HUM)
Insider Ownership Percentage: 0.80%Insider Trades by Quarter for Humana (NYSE:HUM)
Institutional Ownership Percentage: 95.11%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/1/2017||Elizabeth D Bierbower||Insider||Sell||9,786||$259.00||$2,534,574.00|| |
|9/1/2017||Timothy S Huval||VP||Sell||7,803||$258.14||$2,014,266.42|| |
|8/23/2017||William Kevin Fleming||Insider||Sell||3,071||$250.98||$770,759.58|| |
|8/11/2017||Bruce D Broussard||CEO||Sell||12,000||$251.88||$3,022,560.00|| |
|8/10/2017||M Todoroff Christopher||VP||Sell||22,935||$252.52||$5,791,546.20|| |
|6/28/2017||Brian P Leclaire||SVP||Sell||4,971||$240.00||$1,193,040.00|| |
|5/26/2017||Heidi S Margulis||VP||Sell||1,500||$231.96||$347,940.00|| |
|5/5/2017||Jody L Bilney||SVP||Sell||4,600||$230.16||$1,058,736.00|| |
|5/4/2017||Bruce D Broussard||CEO||Sell||118,231||$225.82||$26,698,924.42|| |
|5/4/2017||Timothy S Huval||VP||Sell||13,939||$225.86||$3,148,262.54|| |
|3/21/2017||Jody L Bilney||SVP||Sell||4,348||$213.80||$929,602.40|| |
|3/6/2017||James E Murray||COO||Sell||31,151||$213.62||$6,654,476.62|| |
|3/3/2017||Cynthia H Zipperle||VP||Sell||1,885||$213.37||$402,202.45|| |
|2/24/2017||Brian P Leclaire||SVP||Sell||4,971||$204.81||$1,018,110.51|| |
|2/22/2017||Brian P Leclaire||SVP||Sell||26,894||$205.24||$5,519,724.56|| |
|2/22/2017||James E Murray||COO||Sell||9,523||$204.69||$1,949,262.87|| |
|2/22/2017||Roy A Beveridge||VP||Sell||4,832||$205.73||$994,087.36|| |
|2/21/2017||Bruce D Broussard||CEO||Sell||104,256||$205.23||$21,396,458.88|| |
|2/21/2017||Cynthia H Zipperle||CAO||Sell||4,213||$204.67||$862,274.71|| |
|2/21/2017||David A. Jr/Ky Jones||Director||Sell||27,000||$205.04||$5,536,080.00|| |
|2/21/2017||James E Murray||COO||Sell||70,332||$205.20||$14,432,126.40|| |
|2/21/2017||Jody L Bilney||SVP||Sell||6,087||$204.72||$1,246,130.64|| |
|2/21/2017||M Todoroff Christopher||VP||Sell||24,140||$205.33||$4,956,666.20|| |
|2/25/2016||Brian P Leclaire||SVP||Sell||183||$176.11||$32,228.13|| |
|3/11/2015||James E Murray||COO||Sell||35,220||$160.90||$5,666,898.00|| |
|3/2/2015||Brian P Leclaire||SVP||Sell||5,500||$161.79||$889,845.00|| |
|2/25/2015||Bruce D Broussard||CEO||Sell||41,105||$165.29||$6,794,245.45|| |
|2/25/2015||David A Jr/Ky Jones||Director||Sell||6,100||$165.39||$1,008,879.00|| |
|2/24/2015||Heidi S Margulis||VP||Sell||3,665||$164.44||$602,672.60|| |
|8/22/2014||Brian P Leclaire||SVP||Sell||3,250||$123.04||$399,880.00|| |
|5/15/2014||Heidi Margulis||VP||Sell||3,345||$119.56||$399,928.20|| |
|5/12/2014||Marissa Peterson||Director||Sell||2,026||$123.30||$249,805.80|| |
|3/19/2014||James Murray||COO||Sell||36,833||$116.59||$4,294,359.47|| |
|3/18/2014||M Todoroff Christopher||VP||Sell||8,000||$113.20||$905,600.00|| |
|3/13/2014||Bruce Broussard||CEO||Sell||109,000||$109.84||$11,972,560.00|| |
|3/10/2014||Webster Roy Dunbar||Director||Sell||9,587||$110.30||$1,057,446.10|| |
|12/4/2013||Marissa Peterson||Director||Sell||1,147||$103.54||$118,760.38|| |
|12/2/2013||M Todoroff Christopher||VP||Sell||6,000||$105.50||$633,000.00|| |
|11/26/2013||Heidi Margulis||VP||Sell||5,500||$104.42||$574,310.00|| |
|11/8/2013||David Jr/Ky Jones||Director||Sell||11,000||$95.00||$1,045,000.00|| |
|9/5/2013||Elizabeth D Bierbower||Insider||Sell||17,673||$96.01||$1,696,784.73|| |
|8/30/2013||Heidi Margulis||VP||Sell||3,319||$93.35||$309,828.65|| |
|8/29/2013||David Jr/Ky Jones||Director||Sell||2,500||$93.01||$232,525.00|| |
|8/23/2013||Elizabeth Bierbower||Insider||Sell||6,063||$94.00||$569,922.00|| |
|8/15/2013||Michael Mccallister||Director||Sell||138,817||$91.49||$12,700,367.33|| |
|8/13/2013||Bruce Perkins||Insider||Sell||9,000||$93.47||$841,230.00|| |
|8/8/2013||Steven Mcculley||VP||Sell||10,000||$92.54||$925,400.00|| |
|8/7/2013||James Bloem||CFO||Sell||33,000||$91.79||$3,029,070.00|| |
|8/1/2013||M Todoroff Christopher||VP||Sell||39,596||$90.30||$3,575,518.80|| |
|6/24/2013||Paul B K Kusserow||SVP||Sell||34,219||$84.60||$2,894,927.40|| |
|6/18/2013||Elizabeth D Bierbower||Insider||Sell||8,033||$83.29||$669,068.57|| |
|5/30/2013||James E Murray||COO||Sell||11,000||$81.96||$901,560.00|| |
|5/9/2013||Michael B Mccallister||Director||Sell||281,312||$77.72||$21,863,568.64|| |
Headline Trends for Humana (NYSE:HUM)
Latest Headlines for Humana (NYSE:HUM)
Loading headlines, please wait.
Humana (HUM) Chart for Sunday, October, 22, 2017